Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins
  • Neoplasms

abstract

  • The knowledge gained thus far provides perhaps only a glimpse at the potential of HSP90 for which there is still much work to be done. Lessons from the clinical trials suggest that HSP90 therapy would advance at a faster pace if patient selection and tumor pharmacokinetics of these drugs were better understood and applied to their clinical development. It is also evident that combining HSP90 inhibitors with other potent anticancer therapies holds great promise not only due to synergistic antitumor activity but also due to the potential of prolonging or preventing the development of drug resistance.

publication date

  • January 2014

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4161020

Digital Object Identifier (DOI)

  • 10.1517/13543784.2014.902442

PubMed ID

  • 24669860

Additional Document Info

start page

  • 611

end page

  • 28

volume

  • 23

number

  • 5